Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking MariMed’s growth across multiple state cannabis markets means wading through hundreds of pages of dense disclosures. Crop-yield tables in one state, licensing updates in another—plus executive stock moves timed around new dispensary launches—make each MariMed annual report 10-K simplified anything but simple.
Stock Titan solves that problem. Our AI parses every form as it hits EDGAR, turns accounting jargon into plain language, and delivers MariMed Form 4 insider transactions real-time notifications minutes after executives file. Whether you need the latest MariMed quarterly earnings report 10-Q filing or a quick take on a sudden MariMed 8-K material events explained, you’ll find it here—already summarized, searchable, and linked to the source PDF.
Use cases investors rely on:
- Spot patterns in MariMed insider trading Form 4 transactions before key product launches.
- Compare segment revenue trends with our MariMed earnings report filing analysis dashboards.
- Review pay packages in the MariMed proxy statement executive compensation section without scrolling through appendices.
- Save hours by understanding MariMed SEC documents with AI instead of line-by-line reading.
From 10-K risk factors tied to state cultivation limits to sudden capital raises disclosed in 8-Ks, every filing on this page is tagged, summarized, and cross-linked. In short, MariMed SEC filings explained simply—so you can act on insights, not just information.
Timothy Shaw, Chief Operating Officer and director of Marimed Inc. (MRMD), reported vesting and related transactions on 09/15/2025. 81,772 restricted stock units (RSUs) converted into 81,772 shares and were reported as acquired at $0 per share; the RSUs were granted on May 23, 2025 and the remaining portion will vest on December 15, 2025. To satisfy tax withholding on the vesting, 24,001 shares were withheld by the issuer at an effective price of $0.1374 per share. Following these transactions, the filing shows 9,048,361 shares beneficially owned directly and 2,000,000 shares held indirectly by the Shaw Family Trust (for the benefit of the reporting person’s children), of which Mr. Shaw disclaims beneficial ownership.
Jon R. Levine, President, CEO, Director and 10% owner of MariMed Inc. (MRMD), reported transactions on 09/15/2025. He received 89,860 restricted stock units (RSUs) that vest in part on 12/15/2025 and convert one-for-one into common shares. The filing shows 26,374 shares were withheld to satisfy tax obligations related to the RSU vesting, and 89,860 shares were recorded as acquired at $0 in connection with the RSU grant. Following these transactions, Levine directly beneficially owns 20,847,234 and indirectly owns 6,684,640 shares held by the Jon Levine Family Trust, totaling disclosed influence over the issuer.
Mario Pinho, Chief Financial Officer of Marimed Inc. (MRMD), reported transactions dated 09/15/2025. The filing shows 16,076 restricted stock units (RSUs) treated as acquired and convertible one-for-one into common shares, and 4,574 shares withheld to satisfy tax withholding at a reported price of $0.1374 per share. Following the reported activity the filing lists 157,386 shares beneficially owned directly by the reporting person. The RSUs were originally granted May 9, 2025, and remaining RSUs vest on December 15, 2025, under the award agreement. The Form 4 was signed 09/16/2025.
Ryan Crandall, Chief Commercial Officer of MariMed, Inc. (MRMD), reported equity changes on 09/15/2025. On that date 62,901 restricted stock units (RSUs) vested and are convertible one-for-one into common shares. The issuer withheld 18,462 shares to satisfy tax withholding related to the RSU vesting. Following these transactions the reporting person is shown as beneficially owning 727,667 shares of common stock. The RSUs were originally granted on May 9, 2025, and the remaining portion of that award is scheduled to vest on December 15, 2025 under the award agreement.
FAQ
What is the current stock price of Marimed (MRMD)?
What is the market cap of Marimed (MRMD)?
